{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:55:49Z","timestamp":1760244949317,"version":"build-2065373602"},"reference-count":54,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":4602,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1016\/j.exphem.2009.07.011","type":"journal-article","created":{"date-parts":[[2009,8,4]],"date-time":"2009-08-04T04:56:19Z","timestamp":1249361779000},"page":"1266-1273","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacious but insidious: A retrospective analysis of fludarabine-induced myelotoxicity using long-term culture\u2013initiating cells in 100 follicular lymphoma patients"],"prefix":"10.1016","volume":"37","author":[{"given":"Andrea","family":"Janikova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zdenek","family":"Koristek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaroslava","family":"Vinklarkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Pavlik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Sticha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milan","family":"Navratil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zdenek","family":"Kral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Vasova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiri","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2009.07.011_bib1","first-page":"75","article-title":"Natural history of and therapy for the indolent non-Hodgki\u0144s lymphomas","volume":"20","author":"Horning","year":"1993","journal-title":"Semin Oncol"},{"key":"10.1016\/j.exphem.2009.07.011_bib2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1200\/JCO.1995.13.1.140","article-title":"Patterns of survival in patients with current follicular lymphoma: a 20-year study from a single center","volume":"13","author":"Johnson","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2009.07.011_bib3","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.07.011_bib4","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine and prednisone alone in patients with previously untreated advanced follicular lymphoma","volume":"26","author":"Marcus","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2009.07.011_bib5","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/(SICI)1099-1069(199809)16:3<107::AID-HON630>3.0.CO;2-7","article-title":"Treatment of indolent lymphoma with fludarabine-mitoxantron: a phase II trial","volume":"16","author":"Emmanouilides","year":"1998","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.exphem.2009.07.011_bib6","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1200\/JCO.1996.14.4.1262","article-title":"Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma","volume":"14","author":"McLaughlin","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2009.07.011_bib7","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3324\/haematol.11671","article-title":"High clinical and molecular responses rates with fludarabine, cyclophopshamide and mitoxantrone in previously untreated patients with advanced stage of follicular lymphoma","volume":"93","author":"Montoto","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2009.07.011_bib8","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.1182\/blood-2001-12-0269","article-title":"Fludarabine, mitoxantron, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma","volume":"100","author":"Tsimberidou","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.07.011_bib9","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1046\/j.1365-2141.2001.03014.x","article-title":"Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone","volume":"114","author":"Di Gaetano","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2009.07.011_bib10","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/cncr.22740","article-title":"Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma","volume":"110","author":"Sacchi","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.exphem.2009.07.011_bib11","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1182\/blood-2004-08-3035","article-title":"Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha","volume":"105","author":"McLaughlin","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.07.011_bib12","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cncr.21151","article-title":"Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen","volume":"104","author":"Tsimberidou","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.exphem.2009.07.011_bib13","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1023\/A:1008399623564","article-title":"High-dose therapy with autologous stem cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol","volume":"11","author":"Brice","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.exphem.2009.07.011_bib14","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood.V97.2.404","article-title":"High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial","volume":"97","author":"Horning","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.07.011_bib15","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1046\/j.1365-2141.1998.00960.x","article-title":"Factors associated with successful mobilisation of peripheral blood progenitor cells in 200 patients with lymphoid malignancies","volume":"103","author":"Ketterer","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2009.07.011_bib16","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3109\/10428190009057639","article-title":"Fludarabine containing-regimens may adversely affect peripheral blood stem cell collection in low-grade non-Hodgkin lymphoma patients","volume":"37","author":"Laszlo","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2009.07.011_bib17","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1046\/j.1365-2141.1999.01379.x","article-title":"Fludarabine containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients","volume":"105","author":"Visani","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2009.07.011_bib18","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1200\/JCO.1998.16.4.1554","article-title":"Back-up bone marrow is frequently ineffective in patients with poor peripheral-blood stem-cell mobilization","volume":"4","author":"Watts","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2009.07.011_bib19","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1046\/j.1365-2141.2000.01900.x","volume":"108","author":"Michallet","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2009.07.011_bib20","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1600-0609.1998.tb01055.x","article-title":"Evaluation of marrow and blood haematopoietic progenitors in chronic lymphocytic leukemia before and after chemotherapy","volume":"61","author":"Sala","year":"1998","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.exphem.2009.07.011_bib21","first-page":"311","article-title":"Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma","volume":"4","author":"Moskowitz","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2009.07.011_bib22","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/jcp.1040910303","article-title":"Conditions controlling proliferation of haematopoietic stem cells in vitro","volume":"91","author":"Dexter","year":"1977","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.exphem.2009.07.011_bib23","series-title":"Peripheral Blood Stem Autografts","first-page":"26","article-title":"Biology of haematopoietic stem cells","author":"Gordon","year":"1993"},{"key":"10.1016\/j.exphem.2009.07.011_bib24","series-title":"Hematological Oncology","first-page":"73","article-title":"The bone marrow stromal microenvironment","author":"Gordon","year":"1994"},{"key":"10.1016\/j.exphem.2009.07.011_bib25","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1182\/blood.V74.5.1563.1563","article-title":"Characterization and partial purification of human marrow cells capable of initiating long-term hematopoiesis in vitro","volume":"74","author":"Sutherland","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.07.011_bib26","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1073\/pnas.87.9.3584","article-title":"Functional characterisation of individual human hematopoietic stem cells cultured at limiting dilutions on supportive marrow stromal layers","volume":"87","author":"Sutherland","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2009.07.011_bib27","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1089\/152581699320207","article-title":"Bone marrow processing for transplantation using the COBE spectra cell separator","volume":"8","author":"Ko\u0159\u00edstek","year":"1999","journal-title":"J Hematother Stem Cell Res"},{"key":"10.1016\/j.exphem.2009.07.011_bib28","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1182\/blood.V83.12.3787.3787","article-title":"Patients characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma","volume":"83","author":"Haas","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.07.011_bib29","first-page":"11","article-title":"Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in patients with lymphoma, myeloma and solid tumors","volume":"9","author":"Kotasek","year":"1992","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2009.07.011_bib30","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/cncr.10364","article-title":"Diagnostic utility of bilateral bone marrow examination","volume":"94","author":"Wang","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.exphem.2009.07.011_bib31","doi-asserted-by":"crossref","first-page":"3833","DOI":"10.4049\/jimmunol.142.11.3833","article-title":"Numbers and functions of transplantable primitive immunohematopoietic stem cells. Effect of age","volume":"142","author":"Harrison","year":"1989","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2009.07.011_bib32","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1182\/blood-2004-11-4282","article-title":"Effects of aging on the homing and engraftment of murine hematopoietic stem and progenitor cells","volume":"106","author":"Liang","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.07.011_bib33","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1084\/jem.192.9.1273","article-title":"Age-associated characteristics of murine hemopoietic stem cells","volume":"192","author":"Sudo","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.exphem.2009.07.011_bib34","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1046\/j.1365-2141.2001.02604.x","volume":"112","author":"Boiret","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2009.07.011_bib35","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1002\/cncr.21882","article-title":"Fludarabine, Cyclophosphamide, and Rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent Non-Hodgkin lymphoma","volume":"106","author":"Tam","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.exphem.2009.07.011_bib36","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.bbmt.2008.11.028","article-title":"Treatment with plerixafor in non-Hodgki\u0144s lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient","volume":"15","author":"Stiff","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2009.07.011_bib37","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S1470-2045(08)70039-1","article-title":"Fludarabine and mitoxantrone followed by yttrium-90-ibritumomab tiuxetan in previously untreated patients with follicular lymphoma trial: a phase II non-randomised trial (FLUMIZ)","volume":"9","author":"Zinzani","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.exphem.2009.07.011_bib38","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.exphem.2006.12.006","article-title":"Long-term lymphoma survivors following high-dose chemotherapy and autograft: evidence of permanent telomere shortening in myeloid cells, associated with marked reduction of bone marrow hematopoietic stem cell reservoir","volume":"35","author":"Rocci","year":"2007","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2009.07.011_bib39","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1023\/A:1008381105849","article-title":"A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma","volume":"11","author":"Crawley","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.exphem.2009.07.011_bib40","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/cncr.22093","volume":"107","author":"Nickening","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.exphem.2009.07.011_bib41","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood.V95.10.3052","article-title":"Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma","volume":"95","author":"Hainsworth","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.07.011_bib42","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","article-title":"Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis","volume":"99","author":"Schulz","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.exphem.2009.07.011_bib43","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1023\/A:1007610117810","article-title":"Differential toxicity of anticancer drugs on late (GM-CFC) and early (LTC-IC) hemopoietic progenitors in vitro","volume":"15","author":"Ghielmini","year":"1999","journal-title":"Cell Biol Toxicol"},{"key":"10.1016\/j.exphem.2009.07.011_bib44","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00432-008-0453-8","article-title":"Bendamustine, but not fludarabine, exhibits a low stem cell toxicity in vitro","volume":"135","author":"Schmidt-Hieber","year":"2009","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.exphem.2009.07.011_bib45","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1038\/leu.2008.167","article-title":"Preferential sensitivity of hematopoietic (HPs) and mesenchymal (MPs) progenitors to fludarabine suggests impaired bone marrow niche and HP mobilization","volume":"22","author":"Berger","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2009.07.011_bib46","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1046\/j.1365-2141.1999.01152.x","article-title":"Content of long-term culture-initiating cells, clonogenic progenitors and CD34+ cells in apheresis harvest of normal donors for allogeneic transplantation, and in patients with acute myeloid leukaemia or multiple myeloma","volume":"104","author":"Kasper","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2009.07.011_bib47","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/sj.bmt.1701759","article-title":"Long-lasting decrease of marrow and circulating long-term culture initiating cells after allogeneic bone marrow transplant","volume":"23","author":"Selleri","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2009.07.011_bib48","first-page":"304","article-title":"BCNU treatment of marrow stromal monolayers reversibly alters haematopoiesis","volume":"78","author":"Uhlman","year":"1991","journal-title":"Br\u00a0J\u00a0Haematol"},{"key":"10.1016\/j.exphem.2009.07.011_bib49","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1046\/j.1365-2141.1998.00967.x","article-title":"Quantitative and qualitative alterations of long-term culture-initiating cells in patients with acute leukaemia in complete remission","volume":"103","author":"Yao","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2009.07.011_bib50","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/hon.2900110106","article-title":"COPP chemotherapy for elderly patients with intermediate and high grade non-Hodgki\u0144s lymphoma","volume":"11","author":"Liang","year":"1993","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.exphem.2009.07.011_bib51","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1159\/000163057","article-title":"Procarbazine and CCNU as initial treatment in gliomatosis cerebri","volume":"75","author":"Glas","year":"2008","journal-title":"Oncology"},{"key":"10.1016\/j.exphem.2009.07.011_bib52","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.2174\/092986708784567707","article-title":"Procarbazine\u2014a traditional drug in the treatment of malignant gliomas","volume":"15","author":"Goerne","year":"2008","journal-title":"Curr Med Chem."},{"key":"10.1016\/j.exphem.2009.07.011_bib53","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1212\/01.wnl.0000197792.73656.c2","article-title":"PCV chemotherapy for recurrent glioblastoma","volume":"66","author":"Schmidt","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.exphem.2009.07.011_bib54","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2165\/00003088-200746040-00005","article-title":"Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgki\u0144s lymphoma and its effect on myelotoxicity","volume":"46","author":"Wilde","year":"2007","journal-title":"Clin Pharmacokinet"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X09003129?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X09003129?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:27:26Z","timestamp":1759566446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X09003129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":54,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["S0301472X09003129"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2009.07.011","relation":{},"ISSN":["0301-472X"],"issn-type":[{"type":"print","value":"0301-472X"}],"subject":[],"published":{"date-parts":[[2009,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacious but insidious: A retrospective analysis of fludarabine-induced myelotoxicity using long-term culture\u2013initiating cells in 100 follicular lymphoma patients","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2009.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}